HopeStage
Back to all studies
CompletedNCT04417049

Pentoxifylline for Depression in Bipolarity

About this title

Treatment of Bipolar Depression With Pentoxifylline

Read the official source — NCT04417049
Medication studyAges 18–65Canada
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
TorontoSee all locations and recruitment
Study phase
Early phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: July 12, 2021
Recruitment status
Completed
Enrollment listed in the registry
6
Sponsor
University Health Network, Toronto
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Early Phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
Locations
Canada
Age range
From 18 Years to 65 Years
Official registry ID
NCT04417049
Official title
Show the full official title

Pentoxifylline for Bipolar Depression: A Proof-of-Concept Feasibility Study

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Toronto

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University Health Network, Toronto, a university.

Did this study involve medication?

Yes. The study involved medication, including Pentoxifylline 400 MG.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies